Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 124

Sort by

Sort Order Select

Journal Articles

T-Cell Reconstitution after Unrelated Donor HSCT Using Immunotherapy with CD25/71 Allodepleted Donor T Cells: Results of the Randomised Icat Study

Blood (2019) 134 (Supplement_1): 1995.

https://doi.org/10.1182/blood-2019-124404

Published: 2019

Journal Articles

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

Blood (2019) 134 (Supplement_1): 3000.

https://doi.org/10.1182/blood-2019-126744

Published: 2019

Journal Articles

The Splenic Microenvironment Is a Novel Site of Relapse Following ABT-199 Treatment

Alessandra Di Grande, BSc, Sofie Piers, Pieter Van Vlierberghe, PhD, Triona Ni Chonghaile, PhD BSc

Blood (2019) 134 (Supplement_1): 3800.

https://doi.org/10.1182/blood-2019-127970

Published: 2019

Journal Articles

2018 Evidence Base of Patient Blood Management - Recommendations from the First International Consensus Conference, Frankfurt/Main, Germany

Markus M. Mueller, MD, Hans van Remoortel, Patrick Meybohm, Kari Aranko, Mike Murphy, MD, Jeffrey L. Carson, MD, Erhard Seifried, MD PhD

Blood (2019) 134 (Supplement_1): 4982.

https://doi.org/10.1182/blood-2019-130601

Published: 2019

Journal Articles

Analysis of Outcomes of Younger (≤ 55 Years) Compared with Older (> 55 Years) Patients with Chronic Lymphocytic Leukaemia (CLL) in Seven Studies Conducted By the German CLL Study Group (GCLLSG)

Nisha De Silva, MBBS, MRCP, FRCPath, Sandra Robrecht, PhD, Can Zhang, PhD, Paula Cramer, Anna- Maria Fink, MD, Kirsten Fischer, MD, Valentin Goede, MD, Carmen D. Herling, MD PhD, Manuela Hoechstetter, MD, Clemens-Martin Wendtner, MD, Michael Hallek, MD, Barbara F. Eichhorst, MD

Blood (2019) 134 (Supplement_1): 4293.

https://doi.org/10.1182/blood-2019-126528

Published: 2019

Journal Articles

First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)

David I Marks, MBBS, PhD FRCPath, Amy A. Kirkwood, MSc, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, Melanie Aguiar, BSc, Katharine E Bailey, MBBS, FRCPath, MA, MRCP, Brendan Beaton, MD, Laura Clifton-Hadley, PhDBSc, Emma Lawrie, BSc, SooWah Lee, MSc, Andrew K McMillan, FRCP, Anthony V. Moorman, PhD, Rachel J. Mitchell, MSc, Pip Patrick, PhDMSc,MA, Tobias F Menne, MD PhD FRCPath, Paul Smith, Bela Wrench, MBBS, MD MRCP, FRCPath, Krisztina Zuborne Alapi, MSc, Adele K. Fielding, MBBS,PhDFRCP,FRCPath

Blood (2019) 134 (Supplement_1): 739.

https://doi.org/10.1182/blood-2019-123374

Published: 2019

Journal Articles

Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial

James Croft, BSc, MBBS, MRCP, Andrew Hall, Katrina Walker, Amy L Sherborne, PhD, Sidra Ellis, Amy Price, Debbie Sherratt, Sadie Reed, PhD, Charlotte Pawlyn, BA, PhD MBBChir, MRCP, FRCPath, Mamta Garg, Kevin Boyd, Gordon Cook, Sarah R Brown, PhD MSc, BSc, Martin Kaiser, MD

Blood (2018) 132 (Supplement 1): 3274.

https://doi.org/10.1182/blood-2018-99-111835

Published: 2018

Journal Articles

Outcome of Infants Younger Than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol; Results from an International Randomised Study

Blood (2018) 132 (Supplement 1): 655.

https://doi.org/10.1182/blood-2018-99-112854

Published: 2018

Journal Articles

Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials

Robert K. Hills, MA,DPhil,MSc, Rosemary Gale, PhD, David C. Linch, Brian J.P Huntly, Elli Papaemmanuil, PhD, Paresh Vyas, Alan K. Burnett, MD, Nigel H. Russell

Blood (2018) 132 (Supplement 1): 664.

https://doi.org/10.1182/blood-2018-99-116482

Published: 2018

Journal Articles

Fatigue, Quality of Life, and Physical Fitness Following an Exercise Intervention in Survivors of Multiple Myeloma: A Randomised Controlled Trial Using a Zelen Design

Joanne Sowter, MSc, Dimitrios A Koutoukidis, PhD, Maggie Heinrich, PhD, Orla McCourt, MSc, Allan Hackshaw, Rebecca Beeken, PhD, Dunnya De-Silva, Stephanie Philpott, MSc, Ali Rismani, MBBS, Neil K Rabin, MD, Rakesh Popat, MBBS, BSc, MRCP, FRCPath, PhD, Charalampia Kyriakou, MD PhD, Atul Mehta, FRCP, Bruce Paton, PhD, Abigail Fisher, PhD, Kwee Yong, PhD

Blood (2018) 132 (Supplement 1): 974.

https://doi.org/10.1182/blood-2018-99-111403

Published: 2018

Journal Articles

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Devinder Gill, MD MRCP, FRCPath, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Leanne Berkahn, MD, David Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Rosemary Anne Harrup, MD, Naomi J. Mackinlay, MB BS, FRACP, FRCPA, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Xavier Badoux, MBBS, AB, FRACP, FRCPA, Oliver Giles Best, PhD BSc, Bryone Jean Kuss, PhD BMBS, FRCPA, FRACP

Blood (2018) 132 (Supplement 1): 4432.

https://doi.org/10.1182/blood-2018-99-114064

Published: 2018

Journal Articles

Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation

Gilles Andre Salles, Wojciech Jurczak, David J. Andorsky, MD, Donald P. Quick, MD, Jack W. Singer, MD, Simran Bedi Singh, Lixia Wang, PhD, Anton Egorov, MD, Christine Gabarroca, MSc, Ruth Pettengell, MD

Blood (2018) 132 (Supplement 1): 4189.

https://doi.org/10.1182/blood-2018-99-112455

Published: 2018

Journal Articles

Comparing Randomized Controlled Data with Grouped Data from the Literature to Inform Decision Making When Standard of Care Has Low Level of Evidence Available

Valeska Andreozzi, PhD, Björn Vandewalle, PhD, Jorge Parreira, MSc

Blood (2018) 132 (Supplement 1): 5920.

https://doi.org/10.1182/blood-2018-99-118601

Published: 2018

Journal Articles

Sustainability of Hematological and Clinical Benefits to HU Administration in the Prevention of Sickle-Cell Vaso-Occlusive Crises in Routine Practice

Ersi Voskaridou, MD, Lena Oevermann, MD, Corinne Armari-Alla, MD, Uwe Kordes, MD MRCP, Frédéric Galactéros, MDPhD, Malika Benkerrou, MD, Isabelle Thuret, MD, Dominique Steschenko, MD

Blood (2018) 132 (Supplement 1): 855.

https://doi.org/10.1182/blood-2018-99-116040

Published: 2018

Journal Articles

Hypophosphatemia after High Dosage Iron Substitution with Ferric Carboxymaltose (FCM) and Iron Isomaltoside (IM) — the Randomised Controlled Home Afers 1 Trial

Insa E. Emrich, MD, Fabio Lizzi, Seiler-Mußler Sarah, MD, Christian Ukena, MD, Dominic Kaddu-Mulindwa, MD, Michael Böhm, MD, Stephan Stilgenbauer, Danilo Fliser, MD, Vincent Brandenburg, Gunnar Heine, MD

Blood (2018) 132 (Supplement 1): 3627.

https://doi.org/10.1182/blood-2018-99-114386

Published: 2018

Journal Articles

The Contribution of Gene Mutations to Long-Term Clinical Outcomes: Data from the Randomised UK LRF CLL4 Trial

Blood (2017) 130 (Supplement 1): 259.

https://doi.org/10.1182/blood.V130.Suppl_1.259.259

Published: 2017

Journal Articles

The Risk-Benefit Balance of Treatments for Hodgkin Lymphoma Reported in the Randomised and Non-Randomised Trial Setting: A Systematic Review

Mehul Dalal, PhD, Stephen Mitchell, PhD, Conor McCloskey, PhD, Erin Zagadailov, PharmD, MS, Ashish Gautam, PhD

Blood (2017) 130 (Supplement 1): 5605.

https://doi.org/10.1182/blood.V130.Suppl_1.5605.5605

Published: 2017

Journal Articles

UKALL 2011: Randomised Trial Investigating a Short Induction Dexamethasone Schedule for Children and Young Adults with Acute Lymphoblastic Leukaemia

Nicholas John Goulden, MD PhD MRCPath, Amy A Kirkwood, John Moppett, MD, Sujith Samarasinghe, Sarah Lawson, MD, Clare Rowntree, MD, Rachael Hough, MD BMBS, FRCP, FRCPath, Rajbir Athwal, Pamela R. Kearns, PhDFRCPC, Ajay Vora, MD

Blood (2017) 130 (Supplement 1): 141.

https://doi.org/10.1182/blood.V130.Suppl_1.141.141

Published: 2017

Journal Articles

Recombinant Human Thrombopoietin (rhTPO) and High-Dose Dexamethasone (HD-DXM) Versus High-Dose Dexamethasone Monotherapy As Frontline Treatment in Newly Diagnosed Adult Immune Thrombocytopenia (ITP): a Prospective, Multicentre, Randomised, Controlled Trial

Blood (2017) 130 (Supplement 1): 13.

https://doi.org/10.1182/blood.V130.Suppl_1.13.13

Published: 2017

Journal Articles

Single Centre Retrospective Analysis of Super-Urgent Laboratory Blood Testing System in Massively Transfused Patients

Muhajir Bawa Mohamed, DM,FRACP,FRCPA,, Gerald Bates, Brenda Johnson, Michael Morse, Waheedha Basheer

Blood (2016) 128 (22): 1461.

https://doi.org/10.1182/blood.V128.22.1461.1461

Published: 2016

NARROW

T-Cell Reconstitution after Unrelated Donor HSCT Using Immunotherapy with CD25/71 Allodepleted Donor T Cells: Results of the Randomised Icat Study

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

The Splenic Microenvironment Is a Novel Site of Relapse Following ABT-199 Treatment

2018 Evidence Base of Patient Blood Management - Recommendations from the First International Consensus Conference, Frankfurt/Main, Germany

Analysis of Outcomes of Younger (≤ 55 Years) Compared with Older (> 55 Years) Patients with Chronic Lymphocytic Leukaemia (CLL) in Seven Studies Conducted By the German CLL Study Group (GCLLSG)

First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)

Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial

Outcome of Infants Younger Than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol; Results from an International Randomised Study

Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials

Fatigue, Quality of Life, and Physical Fitness Following an Exercise Intervention in Survivors of Multiple Myeloma: A Randomised Controlled Trial Using a Zelen Design

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation

Comparing Randomized Controlled Data with Grouped Data from the Literature to Inform Decision Making When Standard of Care Has Low Level of Evidence Available

Sustainability of Hematological and Clinical Benefits to HU Administration in the Prevention of Sickle-Cell Vaso-Occlusive Crises in Routine Practice

Hypophosphatemia after High Dosage Iron Substitution with Ferric Carboxymaltose (FCM) and Iron Isomaltoside (IM) — the Randomised Controlled Home Afers 1 Trial

The Contribution of Gene Mutations to Long-Term Clinical Outcomes: Data from the Randomised UK LRF CLL4 Trial

The Risk-Benefit Balance of Treatments for Hodgkin Lymphoma Reported in the Randomised and Non-Randomised Trial Setting: A Systematic Review

UKALL 2011: Randomised Trial Investigating a Short Induction Dexamethasone Schedule for Children and Young Adults with Acute Lymphoblastic Leukaemia

Recombinant Human Thrombopoietin (rhTPO) and High-Dose Dexamethasone (HD-DXM) Versus High-Dose Dexamethasone Monotherapy As Frontline Treatment in Newly Diagnosed Adult Immune Thrombocytopenia (ITP): a Prospective, Multicentre, Randomised, Controlled Trial

Single Centre Retrospective Analysis of Super-Urgent Laboratory Blood Testing System in Massively Transfused Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only